IDYA

IDEAYA Biosciences Inc. (IDYA) | Rumor.io

IDEAYA Biosciences

IDYA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,656

Bullish sentiment (50-day avg)98%

Price to earnings ratio-29.9

Market capitalization3.7B

Earnings per share-1.92

Dividend yield (TTM)—

Revenue (annual)218.7M

Net income (annual)-113.7M

Social

What share of all stock conversation is about IDYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% 0	0% 0	0% 0

Jun 9

IDEAYA Biosciences, Inc. (IDYA) has priced a $300 million equity offering of common stock and warrants, with shares down 8.6% after the announcement.
The offering includes 5.56 million common shares and 5.56 million pre-funded warrants, priced at $27.00 and $26.9999 per share, respectively.
Analysts and investors are expressing disappointment and frustration with the move, citing concerns about management's decision to dilute shareholders and signal a bleak short-term future for the stock.

Generated by AI

Sentiment

Of the messages about IDYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +2.44	86.4% +3.08
Bearish	—	—	0% -2.44	13.6% -3.08

Bullish· Apr 13

IDEAYA Biosciences' ($IDYA) recent data from the OptimUM-02 trial is highly promising, with the company's drug showing a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the control therapy.
The company's pipeline is strong, with at least three best-in-class/first-in-class assets, and it is fully owned by institutions with a significant cash position.
The stock's price is expected to surge due to the positive trial results, with some analysts predicting a significant increase in the stock's value.

Bearish· Apr 13

The asset's price failed to cross $40 despite pre-market expectations, leading to a decline.
Institutional ownership may be propping up the stock, limiting the potential for a short squeeze.
The company may announce another offering soon, potentially leading to a further decline in the stock price.

Generated by AI

Topics

Of the messages about IDYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	66.78%
Technical Analysis	—	0%	0%	1.98%
Analysts	—	0%	0%	16.8%
Controversies	—	0%	0%	0.44%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	13.99%

Apr 13

IDEAYA Biosciences, Inc. ($IDYA) achieved a major clinical milestone in oncology with positive topline results from the pivotal Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma.
The darovasertib combination met the trial's primary endpoint of a statistically significant improvement in median progression-free survival relative to the investigator choice of therapy arm, with a 58% reduction in risk of disease progression.
IDEAYA plans to submit a new drug application to the FDA in the second half of 2026, with additional details from the OptimUM-02 trial to be provided at a major medical conference in 2026.

Generated by AI

Community

Of the messages about IDYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80.85%	93.1%	74.44%
Newcomers	100%	19.15%	6.9%	25.56%

Regulars· Feb 13

IDEAYA Biosciences has announced a further clinical study collaboration with Gilead Sciences to evaluate the combination of Trodelvy and IDE397 in MTAP-deletion NSCLC.
The company's darovasertib MUM Phase 2/3 trial has been fully enrolled, with a PFS readout expected at the end of the year.
IDEAYA Biosciences has a strong financial position, with $1.1B in cash, cash equivalents, and marketable securities, and anticipates funding operations into at least 2028.

Newcomers· Apr 13

IDEAYA Biosciences' darovasertib + crizotinib combo shows promise in metastatic uveal melanoma, with a median PFS of 6.9 months vs. 3.1 months for investigator's choice therapy.
The OptimUM-02 trial, a joint readout with Servier, achieved a major clinical milestone in oncology, with positive topline results from the pivotal Phase 2/3 trial of darovasertib in combination with crizotinib.
The combination therapy is a major catalyst for IDEAYA Biosciences, with the stock up 20% in premarket, and elevated volatility anticipated due to the significance of the clinical milestone achieved.

Generated by AI

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]

5d agoYahoo Finance

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

20d agoThe Globe and Mail

Also Discussed

Investors talking about IDYA also mention

#	Name	Attention
1	Crinetics Pharmaceuticals IncCRNX	0%0
2	Immunocore Holdings plc ADRIMCR	0%0
3	Edgewise Therapeutics Inc.EWTX	0%new
4	Tango Therapeutics Inc.TNGX	0%new
5	SWTX - SpringWorks Therapeutics, Inc.	——
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	Janux Therapeutics, Inc.JANX	0%0
8	Bicycle Therapeutics plc - ADRBCYC	0%0
9	Celcuity Inc.CELC	0%0
10	Syndax Pharmaceuticals, Inc.SNDX	0%+0

IDEAYA Biosciences Inc.

Healthcare
Biotechnology

IDEAYA Biosciences Inc. is a precision medicine oncology company focused on discovering and developing targeted therapies for cancers defined by specific genetic alterations and biomarker profiles. The company combines small-molecule drug discovery, structural biology, bioinformatics, and translational biomarker expertise to advance investigational medicines designed for molecularly selected patient populations. Its current portfolio spans synthetic lethality, targeted pathway inhibition, and antibody-drug conjugate research across solid tumors, including programs directed at uveal melanoma and other genetically defined cancers. IDEAYA Biosciences Inc. works with a research-driven model that integrates internal discovery capabilities with clinical development and collaboration-based programs, making it a notable participant in the broader oncology innovation landscape. Headquartered in South San Francisco, California, the company is positioned around precision oncology approaches intended to match treatments to the biological drivers of disease.

Website

Location

5000 Shoreline Court

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about IDYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% 0	0% 0	0% 0

Jun 9

IDEAYA Biosciences, Inc. (IDYA) has priced a $300 million equity offering of common stock and warrants, with shares down 8.6% after the announcement.
The offering includes 5.56 million common shares and 5.56 million pre-funded warrants, priced at $27.00 and $26.9999 per share, respectively.
Analysts and investors are expressing disappointment and frustration with the move, citing concerns about management's decision to dilute shareholders and signal a bleak short-term future for the stock.

Generated by AI

Sentiment

Of the messages about IDYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +2.44	86.4% +3.08
Bearish	—	—	0% -2.44	13.6% -3.08

Bullish· Apr 13

IDEAYA Biosciences' ($IDYA) recent data from the OptimUM-02 trial is highly promising, with the company's drug showing a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the control therapy.
The company's pipeline is strong, with at least three best-in-class/first-in-class assets, and it is fully owned by institutions with a significant cash position.
The stock's price is expected to surge due to the positive trial results, with some analysts predicting a significant increase in the stock's value.

Bearish· Apr 13

The asset's price failed to cross $40 despite pre-market expectations, leading to a decline.
Institutional ownership may be propping up the stock, limiting the potential for a short squeeze.
The company may announce another offering soon, potentially leading to a further decline in the stock price.

Generated by AI

Topics

Of the messages about IDYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	66.78%
Technical Analysis	—	0%	0%	1.98%
Analysts	—	0%	0%	16.8%
Controversies	—	0%	0%	0.44%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	13.99%

Apr 13

IDEAYA Biosciences, Inc. ($IDYA) achieved a major clinical milestone in oncology with positive topline results from the pivotal Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma.
The darovasertib combination met the trial's primary endpoint of a statistically significant improvement in median progression-free survival relative to the investigator choice of therapy arm, with a 58% reduction in risk of disease progression.
IDEAYA plans to submit a new drug application to the FDA in the second half of 2026, with additional details from the OptimUM-02 trial to be provided at a major medical conference in 2026.

Generated by AI

Community

Of the messages about IDYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80.85%	93.1%	74.44%
Newcomers	100%	19.15%	6.9%	25.56%

Regulars· Feb 13

IDEAYA Biosciences has announced a further clinical study collaboration with Gilead Sciences to evaluate the combination of Trodelvy and IDE397 in MTAP-deletion NSCLC.
The company's darovasertib MUM Phase 2/3 trial has been fully enrolled, with a PFS readout expected at the end of the year.
IDEAYA Biosciences has a strong financial position, with $1.1B in cash, cash equivalents, and marketable securities, and anticipates funding operations into at least 2028.

Newcomers· Apr 13

IDEAYA Biosciences' darovasertib + crizotinib combo shows promise in metastatic uveal melanoma, with a median PFS of 6.9 months vs. 3.1 months for investigator's choice therapy.
The OptimUM-02 trial, a joint readout with Servier, achieved a major clinical milestone in oncology, with positive topline results from the pivotal Phase 2/3 trial of darovasertib in combination with crizotinib.
The combination therapy is a major catalyst for IDEAYA Biosciences, with the stock up 20% in premarket, and elevated volatility anticipated due to the significance of the clinical milestone achieved.

Generated by AI

IDEAYA Biosciences

Social

Jun 9

Sentiment

Bullish· Apr 13

Bearish· Apr 13

Topics

Apr 13

Community

Regulars· Feb 13

Newcomers· Apr 13

News

IDEAYA Biosciences promotes Michael White to R&D president

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push

IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

Also Discussed

IDEAYA Biosciences Inc.

Company Information

Location

News

IDEAYA Biosciences promotes Michael White to R&D president

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

Cantor Fitzgerald reiterates Ideaya Biosciences stock rating

IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push

IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Monte Rosa Therapeutics (GLUE)

Also Discussed

Social

Jun 9

Sentiment

Bullish· Apr 13

Bearish· Apr 13

Topics

Apr 13

Community

Regulars· Feb 13

Newcomers· Apr 13